Zhejiang Bamboo Pharmaceuticals

Zhejiang Bamboo Pharmaceuticals emerged in 2020 as a pioneering and eco-friendly producer of top-notch pharmaceutical API. Its expansive facility spans approximately 66,000m2, with a dedicated plant area covering 50,000 m2. The company specializes in gabapentin, benzocaine, pregabalin, tranexamic acid, levocarnitine, as well as a food additive: dimethyl dicarbonate. Moreover, each API is accompanied by US DMF, CEP certificate, and written confirmation, solidifying its commitment to quality and compliance. Zhejiang Bamboo Pharmaceuticals sets itself apart as a contemporary and regulatory organization, focusing on both API and formulation drug manufacturing. While the formulation drugs primarily target the domestic market, the company aspires to secure a prominent position as a major supplier for the Chinese '4 + 7' volume procurement program.